

EMEND® (APREPITANT CAPSULES), (APREPITANT ORAL SUSPENSION) AND (FOSAPREPITANT DIMEGLUMINE INJECTION)

Quantity Limits / Length of Authorization

Emend 80 mg Capsules	16 capsules / 21 days
Emend 125 mg Capsules	4 capsules / 21 days
Emend Tri-pack	4 packs / 21 days
Emend 125 mg for Oral Suspension (Single-Dose Kit)	12 kits / 21 days
Emend 150 mg Injection	4 vials / 21 days
Emend 40 mg capsule	6 capsules / 6 months

This drug is indicated for short-term acute use; The duration of 21 days is used for a 28-day fill period.

FDA Indications

1. Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

- Emend oral suspensions are indicated in patients 6 months old and older for use in combination with other antiemetic agents for the prevention of:
 - i. acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
 - ii. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
- Emend capsules are indicated in patients 12 years old and older for use in combination with other antiemetic agents for the prevention of:
 - i. acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
 - ii. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
- Emend (fosaprepitant dimeglumine) injection is indicated in adults for use in combination with other antiemetic agents for the prevention of:
 - i. acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
 - ii. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

2. Prevention of Postoperative Nausea and Vomiting (PONV)



- Emend capsules are indicated in **adults** for the prevention of postoperative nausea and vomiting.

Clinical Criteria for Initial Approval

This medication will be covered with prior authorization when the following criteria are met:

- Patient is NOT currently taking pimizide (Orap[®]); **AND**
- Emend is being prescribed for the prevention of postoperative nausea and vomiting; **OR**
- Emend is being prescribed for the prevention of nausea and vomiting associated with highly or moderately emetogenic chemotherapy **AND** will be used in combination with other antiemetic agents